Novo Nordisk Rises 6% So Far in August: How to Play the Stock
Key Takeaways NVO shares gain 5.8% in August despite guidance cuts after Lilly's oral obesity drug disappoints.Potential FDA approval for 25 mg oral semaglutide could give NVO a first-to-market edge.Next-generation drugs like CagriSema and Amycretin target long-term obesity market growth.Novo Nordisk (NVO) faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating profit growth, resulting in a decline in its share price. The downgrade stems from weaker-than-expe ...